New insights on anticancer glucocorticoid receptor modulators: a patent review (2020-present)
Expert Opinion on Therapeutic Patents · 03.07.2026 · 36 (7) · 665-677
DOI: 10.1080/13543776.2026.2689602 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Expert Opinion on Therapeutic Patents, online erschienen am 19.06.2026. Verfasst von Martina Franzin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational and Advanced Diagnostics, Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Trieste, Italy. Hauptthemen laut MEDLINE: Receptors, Glucocorticoid, Neoplasms, Antineoplastic Agents. Die Arbeit nennt 97 Literaturangaben. Gefördert von: Italian Ministry of Health, Institute for Maternal and Child Health IRCCS “Burlo Garofolo”, Trieste, Italy.
Abstract (Originalsprache)
INTRODUCTION: Selective glucocorticoid receptor modulators (SGRM) have emerged as promising agents to counteract glucocorticoid‑driven chemoresistance, immune suppression, and poor prognosis in solid tumors by modulating glucocorticoid receptor (GR) signaling without losing anticancer immune activity. AREAS COVERED: This review provides a focused update to a previous patent review on SGRM (2014-2020) by summarizing Espacenet-indexed patent applications published between 2020 and 30 April 2026 (PCT/US2020/055498, PCT/US2021/017259, PCT/US2022/042475) describing anticancer strategies. EXPERT OPINION: Collectively, these patents support SGRM in addition to cytotoxic and immunotherapeutic regimens in solid tumors. Preclinical and early‑phase clinical evidence (phase I/II) describes how GR antagonism, continuously or intermittently, lowers elevated neutrophil-to-lymphocyte ratio (NLR), modulates GR‑target transcriptional signatures, and enhances responses to nab‑paclitaxel and anti‑PD‑1 antibodies. Key limitations of these patents consist of evidence based on still limited clinical sample sizes, requiring confirmation in phase III trials, and on benefit enriched in biologically defined subpopulations. From a clinical perspective, these agents could be realistically integrated into anticancer protocols, as they work synergistically with other chemotherapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Translational and Advanced Diagnostics, Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Trieste, Italy.
- Department of Life Sciences, University of Trieste, Trieste, Italy.
- Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy.
ORCID-Profile: Martina Franzin, Marianna Lucafò, Debora Curci, Giuliana Decorti, Gabriele Stocco
Förderung
- Italian Ministry of Health
- Institute for Maternal and Child Health IRCCS “Burlo Garofolo”, Trieste, Italy
Zitieren
APA
Franzin, M., Lucafò, M., Curci, D., Decorti, G., & Stocco, G. (2026). New insights on anticancer glucocorticoid receptor modulators: a patent review (2020-present). Expert Opinion on Therapeutic Patents, 36(7), 665-677. https://doi.org/10.1080/13543776.2026.2689602
Vancouver
Franzin M, Lucafò M, Curci D, Decorti G, Stocco G. New insights on anticancer glucocorticoid receptor modulators: a patent review (2020-present). Expert Opinion on Therapeutic Patents. 2026;36(7):665-677. doi:10.1080/13543776.2026.2689602
BibTeX
@article{Franzin2026,
author = {Franzin, Martina and Lucafò, Marianna and Curci, Debora and Decorti, Giuliana and Stocco, Gabriele},
title = {New insights on anticancer glucocorticoid receptor modulators: a patent review (2020-present)},
journal = {Expert Opinion on Therapeutic Patents},
year = {2026},
volume = {36},
number = {7},
pages = {665--677},
doi = {10.1080/13543776.2026.2689602}
}
EUVIMED